Pasithea Therapeutics (Pasithea Therapeutics) Interest Expense : $0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Pasithea Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Pasithea Therapeutics's interest expense for the three months ended in Mar. 2024 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Pasithea Therapeutics's Operating Income for the three months ended in Mar. 2024 was $ -4.04 Mil. Pasithea Therapeutics's Interest Expense for the three months ended in Mar. 2024 was $ 0.00 Mil. Pasithea Therapeutics has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Pasithea Therapeutics Interest Expense Historical Data

The historical data trend for Pasithea Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pasithea Therapeutics Interest Expense Chart

Pasithea Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Interest Expense

Pasithea Therapeutics Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial										-0.01	-	-	-	-

Pasithea Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Pasithea Therapeutics (NAS:KTTAW) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Pasithea Therapeutics's Interest Expense for the three months ended in Mar. 2024 was $0.00 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-4.04 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $0.00 Mil.

Pasithea Therapeutics's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Pasithea Therapeutics had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Pasithea Therapeutics Corp has enough cash to cover all of its debt. Its financial situation is stable.

Pasithea Therapeutics (Pasithea Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pasithea Therapeutics Corp (NAS:KTTAW) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

KTTA:USA

Address

1111 Lincoln Road, Suite 500, Miami Beach, FL, USA, 33139

Website

https://www.pasithea.com

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders. Epidemiological data indicate neuropsychiatric disorders as being some of the most prevalent, devastating, and yet poorly treated illnesses.